Author:
TANYERİ Mehmet Hanifi,BÜYÜKOKUROĞLU Mehmet Emin,TANYERİ Pelin,ÖZTÜRK Aykut,KELEŞ Rümeysa,BAŞARIR BOZKURT Şeyma Nur,MUTLU Oguz
Reference21 articles.
1. 1- Jacek Tomaszewski. Postmenopausal overactive bladder. Prz Menopauzalny 2014;13(6):313-329.
2. 2- Corsos J, Przydacz M, Campeau L, Witten J, Hickling D, Honeine C, et. al. CUA Guideline On Adult Overactive Bladder 2017;11(5): E142–E173.
3. 3- Lam S and Hilas O. Pharmacologic management of overactive bladder. Clinical Interventions in Aging 2007;2(3) 337–345.
4. 4-Yoshimura N and Chancellor MB. Current and future pharmacological treatment for overactive bladder. J Urol. 2002;168:1897–1913.
5. 5-Product Information, 2004a. Ditropan XL®, oxybutynin chloride extendedrelease tablets. Ortho-McNeil Pharmaceutical, Inc., New Jersey, USA.